Pet health insurer Trupanion Q3 revenue beats estimates on subscription growth

Reuters
Nov 07
Pet health insurer <a href="https://laohu8.com/S/TRUP">Trupanion</a> Q3 revenue beats estimates on subscription growth

Overview

  • Trupanion Q3 revenue grows 12% yr/yr, beating analyst expectations

  • Net income for Q3 rises to $5.9 mln, reflecting record profitability

  • Company secures $120 mln credit facility with PNC Bank, enhancing financial flexibility

Result Drivers

  • SUBSCRIPTION GROWTH - Subscription business revenue increased 15% yr/yr, driven by a 5% rise in subscription pet enrollments

  • CREDIT FACILITY - New $120 mln credit facility with PNC Bank enhances financial flexibility and supports strategic investments

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$366.92 mln

$361 mln (4 Analysts)

Q3 Net Income

$5.87 mln

Q3 Operating Expenses

$54.20 mln

Q3 Operating income

$5.86 mln

Q3 Pretax Profit

$6.60 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the life & health insurance peer group is "buy"

  • Wall Street's median 12-month price target for Trupanion Inc is $57.00, about 25.5% above its November 5 closing price of $42.49

  • The stock recently traded at 125 times the next 12-month earnings vs. a P/E of 274 three months ago

Press Release: ID:nGNX34vQCx

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10